Teva Sees 2013 Profit Below Estimates

Teva Sees 2013 Profit Below Estimates

Akos Stiller/Bloomberg

Teva’s shares have underperformed competitors’ this year amid speculation the multiple sclerosis medicine Copaxone may lose market share to new treatments such as Novartis AG’s Gilenya.